Treating Treatment-resistant Depression with Esketamine Nasal Spray When All Therapeutic Options Have Been Exhausted : Clinical Experience from a Spanish Cohort of Expanded Use
Vendrell-Serres, Júlia (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal)
Soto-Angona, Óscar (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal)
Rodríguez-Urrutia, Amanda (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal)
Inzoli, Benedetta (Hospital Universitari Vall d'Hebron)
González, Antonia López (Hospital Universitari Vall d'Hebron)
Ramos-Quiroga, Josep Antoni (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal)

Data:	2023
Resum:	Treatment Resistant Depression (TRD) is commonly defined as the lack of response to two or more antidepressants with different mechanisms of action. Up to 30% of patients diagnosed with major depressive disorder might be considered to present TRD. The objective of this study was to assess the effectiveness and tolerability of esketamine in patients diagnosed with TRD, who were referred to our program after exhausting all available treatments. A secondary objective consisted in researching the relationship between response and previous use of electroconvulsive therapy. A prospective, observational study was carried out in patients enrolled in the expanded use of esketamine in our center. They received esketamine prior to its marketing authorisation, for therapeutic purposes. Sixteen subjects were analyzed. Effectiveness was assessed with the Montgomery-Asberg depression rating scale (MADRS). Patients were followed up to 4 months after the administration. Esketamine showed a rapid, robust effect in improving depressive symptoms, with no specific correlation between outcome and any demographic or clinical traits evaluated. No differences were found between patients that previously received Electroconvulsive Therapy, and those that didn't. 10 out of 16 patients responded (> 50% change in baseline MADRS scores), but only five achieved remission (< 12 points in the global MADRS score). We provide some recommendations, based on clinical experience, to improve tolerability and adherence, and to manage adverse effects. Results suggest that esketamine is a safe, effective and rapid-acting option for TRD. More studies are needed to properly assess predictors of response outcome.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Esketamine ; Depressive disorder, treatment-resistant ; Prospective study ; Compassionate use
Publicat a:	Clinical Psychopharmacology and Neuroscience, Vol. 22 (september 2023) , p. 159-168, ISSN 2093-4327

DOI: 10.9758/cpn.23.1097
PMID: 38247422

10 p, 337.2 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats